Thursday, June 13, 2024
Loren Armenti/Wharton Alumni Angels Admin
Wharton Alumni Angels has invited 4 Life Sciences companies that have been referred by WAA Members to pitch to WAA Members and Guests on Thursday, 13-Jun-2024 from 4pm - 6:00pm PT // 7pm - 9:00pm ET.
This event is open to both Wharton Alumni Angels Members and non-Members. Attendees are invited and encouraged to participate in the post pitch discussion following the company presentations.
Presenting companies and proposed agenda is below. Click on their company logo to visit them on Dealum and learn more.
Selected companies can also be viewed in the following places:
- DEALUM => Funnel => Pitch Day
- WAA website => Member Portal => Deals, Events and News Updates => Pitch Events
Each presenting company will be allotted 20 minutes for pitch presentation and Member Q&A. The remaining time will be dedicated to a Member and Guest Only Discussion during which each presentation will be discussed.
Zoom joining information will be sent upon registering for this event.
Invited companies are screened by WAA's Screening Committee and selected based on a variety of criteria.
If you would like to recommend a company to Wharton Alumni Angels for funding consideration, please share the link for our FUNDING APPLICATION found on our website (Startup Resources => Get Funded").
PROPOSED AGENDA:
| 4:00pm PT // 7:00pm ET | EyeCheq |
| 4:20pm PT // 7:20pm ET | Harmonic Discovery |
| 4:40pm PT // 7:40pm ET | Thirona Bio |
| 5:00pm PT // 8:00pm ET | Truss Health |
| 5:20pm PT // 8:20pm ET | Post Pitch Discussion (WAA Members and Guests) |
EyeCheq is the only fully autonomous platform that provides diagnostic health/vision testing in retail health clinics
⭐ Sourced by Sophia Lee
PROBLEM: According to the American Optometric Association, 26% of Americans do not visit an eye care professional, and only 50% visit annually, despite 95% of blindness being preventable if detected early. Accessibility, affordability, and awareness are the primary reasons, thus creating an opportunity for a simple, convenient, and affordable solution.
SOLUTION: EyeCheq’s fully autonomous and AI-driven functionality is scalable and meets patients where they frequent, like their pharmacy or a lab. Thus, patients can get their health and vision checked (and close care gaps for diabetic retinopathy). In addition, EyeCheq is developing AI to detect retinal and systemic diseases.
DEAL LEAD: Sophia Lee ([email protected] // @Sophia Lee on Slack)
SUBMIT DUE DILIGENCE QUESTIONS
REGISTER FOR EYECHEQ DUE DILIGENCE CALL ON 20-JUN
Harmonic Discovery is an AI drug discovery company focusing on precision pharmacology.
⭐ Sourced by Joyce Fang
DEAL LEAD: [Looking for volunteers]
PROBLEM: Harmonic Discovery, founded in 2021, is a biotechnology startup building advanced AI tools to create best-in-class kinase inhibitor drugs by leveraging machine learning, generative AI and computational chemistry. Our therapeutic areas of focus include oncology, hematology and autoimmunity.
SOLUTION:Harmonic Discovery applies novel and emerging computational technologies in machine learning to solve difficult problems in drug development. We use our platform technology to develop safer and more effective drugs to solve critical unmet needs for various diseases.
SUBMIT DUE DILIGENCE QUESTIONS
DUE DILIGENCE CALL WITH HARMONIC DISCOVERY CURRENTLY BEING COORDINATED
Thirona Bio is developing a proprietary drug platform to treat both skin and lung fibrosis, as well as certain cancers.
⭐ Sourced by James Carroll
DEAL LEAD: Jim Carroll ([email protected] // @Jim Carroll on Slack)
PROBLEM: People are living with debilitating & disfiguring fibrotic conditions that Thirona is addressing with its TBIO drug platform targeting skin fibrosis, including hypertrophic & keloid scars, scleroderma and skin cancer, as well as lung fibrosis, diseases with high unmet medical need.
SOLUTION: Thirona is developing therapies that are organ-selective and locally acting inhibitors of TGF-β, the primary mediator of fibrosis. High local drug levels and inhibition of all TGF-β isoforms is expected to maximize efficacy, while organ targeting & rapid drug metabolism overcome the key historical safety challenges of systemic anti-TGF-β drugs.
SUBMIT DUE DILIGENCE QUESTIONS
DUE DILIGENCE CALL WITH THIRONA BIO CURRENTLY BEING COORDINATED
AI-Powered Sensor Fusion Platform revolutionizing patient care by reducing morbidity and enhancing recovery
⭐ Sourced by Alireza Salmanzadeh
DEAL LEAD: [Looking for volunteers]
PROBLEM: Surgical site infections (SSIs) lead to patient distress, increased mortality, and heavy financial burdens, costing over $20,000 per admission and extending hospital stays by an average of 9.7 days. SSIs affect 20% of all healthcare-associated infections (HAIs).
SOLUTION: Truss Health’s deep-learning AI remote-patient safety monitoring platform enhances recovery and reduces morbidity by leveraging real-time data and analysis from various sensors(infrared camera, biochemistry test) This platform aggregates, monitors, analyzes, and securely transmits data, offering a comprehensive view of a patient’s health status.
SUBMIT DUE DILIGENCE QUESTIONS
DUE DILIGENCE CALL WITH TRUSS HEALTH CURRENTLY BEING COORDINATED
This is a video event.
Please register below in advance of this meeting.
----------
Wharton Alumni Angels is not a venture fund, an investment bank, a broker/dealer, investment clearing‐house, or an investment advisor. Wharton Alumni Angels is not registered with the U.S. Securities Exchange Commission or any other state’s or nation’s securities commission. For tax, compliance, reporting, legal or other requirements, it is highly recommended that members seek appropriate professional help. No representation or warranty is made as to the accuracy or completeness of the information provided by Wharton Alumni Angels or companies presenting investment opportunities. Wharton Alumni Angels presumes that any offering conducted by companies is a private placement and does not involve a public solicitation of investment.
